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Abstract
Female-controlled contraception/HIV prevention is critical to address health issues associated with gender inequality.
Therefore, a contraceptive which can be administered in tandem with a microbicide to inhibit sexually transmitted
infections, is desirable. Uterine leukemia inhibitory factor (LIF) is obligatory for blastocyst implantation in mice and
associated with infertility in women. We aimed to determine whether a PEGylated LIF inhibitor (PEGLA) was an effective
contraceptive following vaginal delivery and to identify non-uterine targets of PEGLA in mice. Vaginally-applied
125I-PEGLA
accumulated in blood more slowly (30 min vs 10 min) and showed reduced tissue and blood retention (24 h vs 96 h)
compared to intraperitoneal injection in mice. Vaginally-applied PEGLA blocked implantation. PEGLA administered by
intraperitoneal injection inhibited bone remodelling whereas vaginally-applied PEGLA had no effect on bone. Further,
PEGLA had no effect in an animal model of multiple sclerosis, experimental auto-immune encephalomyelitis, suggesting
PEGLA cannot target the central nervous system. Vaginally-administered PEGLA is a promising non-hormonal
contraceptive, one which could be delivered alone, or in tandem with a microbicide. Vaginal application reduced the
total dose of PEGLA required to block implantation and eliminated the systemic effect on bone, showing the vagina is a
promising site of administration for larger drugs which target organs within the reproductive tract.
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Introduction
The World Health Organization has called for the urgent
development of pharmacological, non-hormonal contraceptives
[1]. More than 700,000 maternal deaths, most in the developing
world and related to causes associated with unintended pregnan-
cies, occurred between 1995 and 2000; more than 400,000 of
these deaths resulted from unsafe abortions [2]. Safe, affordable
and reliable contraception improves maternal and child health and
reduces population growth [3], which will also help to reduce the
consequences of climate change [4]. It is estimated that over 200
million women worldwide want, but currently lack, access to
modern contraceptives [4]. Female controlled contraception/HIV
prevention is critical to address health issues associated with
gender inequality [5]. Progress in the contraceptive development
arena has been so poor that a recent report by the United
Kingdom All Party Parliamentary Group on Population, Devel-
opment and Reproductive Health [6] concluded that the
Millennium Development Goals of the United Nations cannot
be met given the levels of population growth in the poorest
countries.
Implantation of a blastocyst into the uterine endometrium is a
critical step for the establishment of pregnancy. Synchronized
endometrial receptivity and blastocyst competence is essential for
implantation and is achieved via a regulated network of paracrine
and autocrine factors, including cytokines [7].
Leukemia inhibitory factor (LIF), an interleukin (IL) 6-type
cytokine, is one of the few molecules obligatory for fertility in mice
[8]. LIF null female mice are infertile due to the failure of
blastocysts to implant into the uterus [8]. In women, LIF
production by the uterine epithelium is maximal during the
period of ‘uterine receptivity’ [9,10,11], a short window during the
menstrual cycle when the uterus is capable of responding to and
allowing blastocyst implantation [7]. Evidence for an important
role of LIF in human implantation comes from clinical studies of
infertile women, who have lower levels of LIF mRNA and protein
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fertile women [12,13,14,15]. In vitro, exogenous LIF enhances the
adhesion of primary human endometrial epithelial cells to
fibronectin [16], an extracellular matrix component present on
trophoectodermal cells of the blastocyst [17] and to collagen IV
[16], present on first trimester human trophoblast [18]. Altogether
these studies suggest that LIF modulates adhesion between
endometrial epithelial and trophoblast cells. We hypothesise that
blockage of LIF action in women would prevent blastocyst
implantation.
In mice, interperitoneal (IP) injections of a highly potent,
PEGylated (conjugated to polyethylene glycol) LIF antagonist
(PEGLA) during the peri-implantation period blocks endometrial
epithelial LIF action and prevents blastocyst implantation [19],
making PEGLA a promising pharmacological contraceptive.
PEGLA antagonises LIF by binding to the LIF receptor (R) but
not recruiting the LIFR signalling component, IL6ST (also known
as gp130), preventing initiation of downstream gene transcription
[20]. Blastocysts recovered from PEGLA-treated females outgrow
normally in culture [19], showing that PEGLA acts only on the
endometrium in mice.
The LIFR is also utilised for signalling by other IL6 family
members including oncostatin M (OSM), ciliary neurotrophic
factor (CNTF) and cardiotrophin 1 (CT-1). The LIF
2/2 mouse is
infertile due to failure of implantation [8] and shows decreased
bone volume associated with increased osteoclast number and size
[21]. The LIFR
2/2 mouse is embryonic lethal and shows
impaired placental formation, decreased bone volume associated
with increased osteoclast number and size, decreased sensory
neuron survival, decreased numbers of spinal and brainstem
astrocytes and elevated liver glycogen [22]. While CT-1 knockout
mice have normal fertility, neonate CT-1 null mice show a similar
phenotype to the LIF
2/2 and LIFR
2/2 mouse [23]. Currently no
information is available as to the non-uterine tissue targets of
PEGLA; however low bone volume in LIF
2/2, CT-1
2/2 and
LIFR
2/2 mice [21,22] and reduced numbers of spinal and
brainstem astrocytes in LIFR
2/2 mice suggests that PEGLA may
also influence bone structure and astrocyte number.
In women, vaginally administered drugs preferentially localise
to the uterus [24,25]. This preferential localisation, termed the
‘uterine first-pass effect’, was identified because of the marked
uterine response to vaginally administered progesterone despite
low serum progesterone concentrations [24]. Subsequent studies
showed that the endometrial concentration of vaginally adminis-
tered drugs was substantially higher than following other routes of
delivery, including intramuscular and oral [26,27,28]. The
mechanism of preferential localisation to the uterus is not clear,
although it seems likely that drugs administered via the vagina are
absorbed into veins within the upper third of the vagina and then
transported by counter-current exchange to the uterine arteries
[25,29,30].
In women, vaginal application has been used as a delivery
method for contraceptives that primarily target the ovary [31,32]
although these are anti-progestins which are very small. PEGLA is
estimated to be ,60 kDa. It is not known whether such a large
molecule can be absorbed by the vagina to enter the blood and
reach the uterus. To the best of our knowledge, the efficacy of
vaginally applied contraceptives that target the uterus has not been
reported. Numerous vaginally delivered microbicides, which
inhibit sexually transmitted infections (STI), including HIV, are
currently undergoing clinical trials. Recently, a clinical trial of
using a vaginal gel formulation of tenofovir, a nucleotide reverse
transcriptase inhibitor, showed significant inhibition of HIV
incidence [33], suggesting that tenofovir could be vaginally
administered in tandem with a contraceptive such as PEGLA,
making a ‘dual-role’ contraceptive, capable of preventing both
pregnancy and STIs.
We hypothesized that PEGLA would localise to the uterus more
rapidly and at a higher concentration following vaginal delivery
than following injection, making vaginal application a promising
contraceptive delivery method for PEGLA in women. Our specific
aims were to: 1. establish the contraceptive efficacy of PEGLA
following vaginal delivery in mice; 2. determine whether bone and
the central nervous system (CNS) are non-uterine targets of
PEGLA in mice and 3. to compare the tissue distribution and half-
life of PEGLA following IP injection and vaginal application in
mice.
Materials and Methods
Animals
C57BL6/J mice (Monash Animal Services, Clayton, WEHI
Bioservices Department, Kew, both VIC, Australia) housed under
conventional conditions, had ad libitium food and water and were
maintained in a 12 h: light-dark cycle. All procedures were
approved by the Monash Medical Centre (B) Animal Ethics
Committee (#MMCB2007/21) or the WEHI Animal Ethics
Committee (#2008.032), and this study followed the NHMRC
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes.
Preparation of PEGylated proteins
PEGLA was produced as previously described [19], except that
Y-NHS-40K (Jenkem Technology, Allen, Texas, USA) was used
for PEGylation.
The in vitro activity of PEGLA was measured using a LIF-
responsive Ba/F3 line stably expressing human LIFR and IL6ST
as previously described [19]. PEGLA produced with the new PEG
compound exhibited a 2-fold increase in the inhibition of LIF-
induced proliferation of Ba/F3 cells [20] compared to the original
PEGLA (Figure S1).
Control PEGylation reagent was generated by incubating Y-
NHS-40K in Milli-Q water for at least 24 h. PEGylated bovine
serum albumin (BSA) or mouse serum albumin (MSA; both
Sigma-Aldrich, Castle Hill, NSW, Australia) were prepared as for
PEGLA except that an anion exchange step was performed.
Vaginal application of PEGLA
Tissue localization of PEGLA. Mated female mice (8 weeks;
n=2/group) were given a single vaginal application of PEGLA
(11.25 mg/g [250 mM]/application) dissolved 1:2 in a placebo gel
(CAPRISA 400 Study Gel, provided by the Consortium for
Industrial Collaboration in Contraceptive Research Program
[CICCR] of the Contraceptive Research and Development
Program [CONRAD]) at 9am on day (D) 3 (day of vaginal
plug detection=D0) and killed after 3 h or 24 h or were given
multiple doses (610) of 3.75 mg/g [83.3 mM]/application
PEGLA during D2–5 and killed on D6. Uteri were dissected
out and fixed in Neutral Buffered Formalin before PEGLA
immunoreactivity in the vagina and uterus was identified as
previously described [34].
Contraceptive efficacy of PEGLA. Mated female mice (8–
10 weeks; n=4/group) were given vaginal applications of PEGLA
at two doses (4.8 mg/g [111 mM] or 5.6 mg/g [111 mM]/
application) or PEGMSA control (4.8 mg/g [111 mM] or
5.6 mg/g [111 mM]/application) dissolved 1:2 in placebo gel
during the peri-implantation period. The mouse vagina can hold
only ,15 ml, thus the dose of PEGLA able to be delivered per
Contraceptive Action of Vaginal LIF Antagonist
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applications at D2 9am, 3pm & 9pm and D3 9am & 3pm. It was
not possible to treat mice with a greater number of applications as
this resulted in abortion in the SHAM treated mice (data not
shown). Treated mice were killed on D6 and the number of CL on
the ovary and IS in the uterus counted.
The effect of PEGLA on long-term fertility. Non-mated
female mice (10 weeks; n=3/group) were given IP injections of
PEGLA (24.9 mg/g [81.5 mM]/injection) or PEGylation reagent
control (PEG; 20 mg/g [100 mM]/injection) at 12pm and 10pm
and the following day at 10am. After 15 days the treated mice
were paired until they plugged. Plugged mice were killed on D10
and the number of implantation sites in the uterus counted.
The effect of PEGLA on bone remodelling. Mated and
non-mated female mice (8–10 weeks; n=4/group) were treated
with PEGLA by IP injection or vaginal application. IP injections of
PEGLA (30 mg/g [100 mM]/injection) or PEGylation reagent
control (PEG; 20 mg/g [100 mM]/injection) were given to mated
and non-mated females at 12pm and 10pm (D2 in mated females)
and the following day at 10am (D3 in mated females). Vaginal
applications of PEGLA (5 mg/g [111 mM]/application) or
PEGMSA (5 mg/g [111 mM]/application) were given to mated
females at D2 9am, 3pm & 9pm and D3 9am & 3pm).
Treated mice were killed on D6 and tibiae analysed as
previously described [35].
Effect of PEGLA on EAE. In mice, LIF and CNTF prevent
worsening of experimental auto-immune encephalomyelitis (EAE),
an inducible animal model of multiple sclerosis [36,37]. We
investigated whether PEGLA could inhibit LIF action in the CNS
and worsen EAE. EAE was induced in male mice (8–10 weeks;
n=8/group) using MOG 35–55 (MEVGWYRSPFSRVVHL
YRNGK) peptide ([38], Mimitopes). MOG 35–55 (final concen-
tration 0.5 mg/ml) was delivered in equal parts peptide (carried in
MT-PBS) and Freund’s Complete Adjuvant (Difco) containing
Mycobacterium tuberculosis H37Ra (4 mg/ml; Difco). Each mouse
received a total dose of 125 mg peptide, via 100 ml subcutaneous
injections in each flank, as well as a subcutaneous injection of 50 ml
in the base of the tail. On the initial day of EAE induction
(designated as D0) and D3, the mice also received an IP injection
of 300 ng of Bordetella Pertussis toxin (List Biological).
Mice that reached EAE grade 2 (see below), were given water
and powdered food in small Petri dishes at the base of the cage for
easy access. Cotton wool buds were also added to cages for extra
warmth. To monitor general health, mice were weighed every
second day. Mice that were considered to be in poor health or that
had lost their righting reflex were euthanized by administration of
100 ml lethabarb (325 mg/mL pentobarbitone sodium, Virbac,
Peakhurst, NSW) via IP injection.
Disease severity was graded by a blinded observer using a
standard EAE scoring system:
0 – No clinical symptoms
1 – Mild tail weakness
1.5 – Mild tail weakness; mild gait abnormality (splayed or high-
stepped)
2 – Complete tail atonia
2.25 – Complete tail atonia; mild gait abnormality
2.5 – Complete tail atonia; moderate gait abnormality (trunk
cannot be raised)
2.75 – Complete tail atonia; paralysis of one hind limb
3 – Complete tail atonia; paralysis of both hind limbs
3.5 – Complete hind limb and tail paralysis plus animal unable
to right when placed supine; animals were euthanized at this point
4 – Death
PEGLA Treatment. Mice received IP injections of PEGLA
(5 mg/g [16.7 mM]/injection) or PEG control (3.3 mg/g
[16.5 mM]/injection) every second day post-induction of EAE.
Serum pNF-H Assay. Fresh blood samples (n=6–7/group),
collected by cardiac puncture after euthanasia and just prior to
transcardial perfusion, were centrifuged at 5000 rpm for 10 min to
separate serum for analysis in the pNF-H ELISA as previously
described [39].
Tissue distribution of
125I-PEGLA following IP injection
and vaginal application
Proteins were radioiodinated as described previously [40]. Non-
pregnant or mated (D2) female mice (n=3/group) were given
125I-PEGLA or control (
125I-PEGBSA) by IP injection (25 mg/g
[83.3 mM] PEGLA plus 4610
6 cpm
125I-PEGLA, dissolved in
sterile saline, total volume: 100 ml) or by vaginal application
(15 mg/g [333.3 mM] PEGLA plus 7610
5 cpm
125I-PEGLA,
carried 1:2 in placebo gel, total volume: 15 ml). At selected times
post-application of the radioligand (10 min, 30 min, 2 h, 6 h, 24 h
and IP only: 48 h, 72 h, 96 h and 120 h), urine was collected by
bladder palpitation, blood collected by cardiac puncture and
stored in EDTA tubes (Microvette, Sarstedt, Technology Park,
SA, Australia) to prevent clotting, and intact organs weighed and
total
125I measured in each using a gamma counter (Packard
Cobra Multi-detector, Packard, Downers Grove, IL).
Protein-bound
125I(
125I-PEGLA or
125I-PEGBSA) in blood was
measured by mixing 100 ml blood with 1 ml of 20% (w/v)
trichloroacetic acid (TCA, Sigma) on ice for 5 min before samples
were spun at 8,0006 g for 1 min. TCA-precipitated
125I was
defined as protein-bound
125I whereas non-precipitable
125I was
considered free-iodine. The
125I content in intact organs was
expressed as counts/mg and in blood and urine as counts/ml. To
compare between IP and vaginally applied PEGLA, the
125I
content was expressed as counts/applied dose (AD) per mg tissue
or ml blood/urine.
Statistics
GraphPad Prisim 5.0 (GraphPad Software, San Diego, CA) was
used for all statistical analyses, except for the EAE study which
used SigmaStat version 2.03 (SPSS Inc). A P value of #0.05 was
considered statistically significant. A Mann-Whitney t-test was
used to compare IS and CL numbers between treatment groups,
125I-PEGLA and
125I-PEGBSA levels in non-mated animals at
24 h after vaginal application,
125I-PEGLA levels between IP
injection and vaginal application at each time-point, bone
parameters between PEGLA and control mice and EAE grades.
Paired t-tests were used to analyse the data from the pNF-H
ELISA. A Kruskal-Wallis one-way ANOVA with Dunn’s post-hoc
test was used to identify differences in
125I counts between time-
points and to compare
125I counts between
125I-PEGLA (mated
and non-mated) and
125I-PEGBSA (non-mated) treated animals at
2 h and 24 h. The pNF-H concentrations were correlated to the
EAE grades using a Pearson correlation.
Results
Vaginally administered PEGLA localized to the uterine
epithelium and blocked implantation
Vaginally applied PEGLA localised to the uterine luminal
epithelium and basal surface of the glandular epithelium at 3 h
and was similarly present at 24 h (Figure S2A–D). Importantly,
the vaginal epithelium remained intact following both single and
repeated (610) applications of PEGLA (Figure S2E–F).
Contraceptive Action of Vaginal LIF Antagonist
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applications; 5.6 mg/g/application) on D2 and D3 blocked
implantation (n=4/group; PEGLA 0/4 females had implantation
sites (IS), 0.0 IS/uterus, average body weight 17.860.3 g;
PEGMSA: 4/4 females had IS, 6.561.3 IS/uterus, average body
weight 18.060.4 g; Figure 1A&B). There was no difference in the
number of corpora lutea (CL) between the PEGLA and PEGMSA
control treatment groups indicating that normal ovulations had
occurred (PEGLA 6.560.6; PEGMSA 8.560.9 CL/mouse;
P=0.1367). By comparison, vaginal administration at the lower
dose (4.8 mg/g/application) of PEGLA did not block implantation
(n=4/group; PEGLA 4/4 females had implantation sites (IS),
10.360.3 IS/uterus, average body weight 21.560.5 g; PEGMSA:
4/4 females had IS, 8.860.8 IS/uterus, average body weight
21.860.5 g; no difference in implantation site number between
PEGLA and PEGMSA treated females: P=0.1367). Histology of
uteri from PEGLA treated females showed the uteri were non-
pregnant and intact (data not shown) as found previously following
IP injection of PEGLA [19].
PEGLA had no effect on subsequent fertility
All non-pregnant females administered PEGLA or PEG by IP
injection mated within 3 days of pairing. No difference in the
number of implantation sites was found on D10 (PEGLA 9.361.5;
PEG 8.061.0 IS/uterus; P=0.3687) indicating that normal
implantation had occurred.
PEGLA inhibited bone remodelling following IP injection
Histomorphometry of the tibia following 3 IP injections of
PEGLA (30 mg/g/injection) to both mated and non-mated
females showed that PEGLA increased trabecular bone volume,
trabecular number and trabecular thickness (Figure 2A–E) in
mated females when compared to PEG treated controls.
Interestingly, mated females had a lower amount of trabecular
bone (Figure 2C–E) than non-mated females on D6 regardless of
treatment. Non-mated females treated with PEGLA had less
osteoid (Figure 2F) and fewer osteoblasts (Figure 2G) and
osteoclasts (Figure 2H) than control females. Mated females
treated with PEGLA also had fewer (Figure 2H) osteoclasts than
control females, but osteoblast and osteoid surface were not
significantly lowered (Figure 2F&G) possibly because the level of
osteoblast and osteoid in mated females was already low compared
to non-mated females (Figure 2F&G).
PEGLA had no effect on bone following vaginal
administration
Histomorphometry of the tibia following 5 vaginal applications
of PEGLA (5 mg/g/application) to mated females (n=2–4/group)
showed no effect on trabecular bone volume, number or thickness
(Figure 3A–D) or on osteoclast/osteoblast number and size
(Figure 3E–I) when compared to PEGMSA-treated controls.
PEGLA had no effect on the central nervous system
PEGLA had no effect on EAE severity as determined by both
motility scoring (Figure 4) and serum phosphorylated Neurofila-
ment-H (pNF-H) levels 19 days after EAE induction (PEGLA:
3.961.4; PEG: 4.761.0 ng/ml; P.0.05). Serum pNF-H levels
were highly correlated with mouse EAE clinical scores (Pearson
correlation coefficient, r=0.735).
PEGLA tissue localisation and tissue half-life
To identify other potential tissue targets of PEGLA, we traced
125I-PEGLA or control,
125I-PEGBSA, following both IP injection
and vaginal application.
PEGLA localised to the liver, ovary, oviduct, spleen and
thyroid following IP injection.
125I-PEGLA was detected in
blood from 10 min to 72 h after injection (Figure 5A). The
concentration of
125I-PEGLA in blood peaked at 6 h post-injection
(Figure 5A). The period of blood retention of
125I was equivalent to
the retention of
125I-PEGLA (Figure S3A) although counts of
125I-
PEGLA were between 53 and 89% of total
125I (Figure S3B),
suggesting that up to 47% of total
125I in blood was free iodine.
After 24 h, most of the
125I had accumulated in the thyroid
(Figure S4). In most tissues
125I accumulation peaked between
10 min and 6 h and fell to low levels by 24 h (Figure S4).
To determine whether the tissue accumulation of PEGLA was
specific (ie. receptor bound) or non-specific (due to protein kinetics
related to size) we compared accumulation of
125I-PEGLA with
accumulation of a similarly sized control,
125I-PEGBSA. In non-
mated females there was no difference in accumulation of
125I-
PEGLA or control in any tissue at 2 h post-injection (Figure 6A;
Figure S5A), but at 24 h post-injection (Figure S5B)
125I-PEGLA
counts were significantly higher than
125I-PEGBSA counts in the
liver (P=0.0258; Figure 6B), ovary (P=0.0429; Figure 6C), oviduct
(P=0.0343; Figure 6D), spleen (P=0.0181; Figure 6E) and thyroid
(P=0.0258;Figure6F)suggesting that PEGLAlocalised to and may
be acting on these tissues. At 2 h post-injection,
125I-PEGLA
accumulation in the heart of mated females was significantly higher
than in the heart of non-mated females (P=0.0349; Figure 6A).
Vaginal application decreased the half-life and tissue
localisation of PEGLA.
125I-PEGLA was detected in blood
from 30 min to 24 h after vaginal application (Figure 5B). The
concentration of
125I-PEGLA in blood peaked at 2 h after
application (Figure 5B). The period of blood retention of
125I
was equivalent to the retention of
125I-PEGLA (Figure S3C),
although counts of
125I-PEGLA were between 37% and 72% of
total
125I counts (Figure S3D), suggesting that up to 63% of total
125I counts in blood was free iodine.
After 24 h, the majority of
125I-PEGLA had accumulated in the
thyroid (Figure S5). In all other tissues (except vagina & urine),
125I-PEGLA accumulation peaked at 2 h after application (Figure
S6). Vaginal accumulation of
125I-PEGLA peaked 30 min
following application (Figure S6) and urine accumulation of
125I-
PEGLA peaked at 10 min and 2 h after application (Figure S6),
suggesting a large amount of
125I-PEGLA was excreted almost
immediately after application. No specific (receptor bound)
accumulation of
125I-PEGLA was found in any tissue at 2 h or
24 h after vaginal application (Figure S7).
Figure 1. PEGLA blocked implantation following vaginal
delivery. Ex vivo uteri following treatment with 5 applications of
5.6 mg/g/application PEGLA (A) or PEGMSA (B) on day 6. Arrows
indicate implantation sites. Bars=1.0 cm.
doi:10.1371/journal.pone.0019665.g001
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injection than vaginal administration
To compare
125I accumulation between the two delivery routes
the tissue
125I counts were normalised to the total
125I counts
administered. At 10 min after administration, accumulation of
125I
in most tissues was significantly lower following vaginal adminis-
tration compared to IP injection (P=0.0286 for all; Figure S8),
except in the pancreas and urine, where
125I accumulation was
equivalent between the two delivery methods, and in the vagina
where
125I accumulation was higher (P=0.0286; Figure S8). At all
time-points after 10 min, except in the bladder (30 min,
P=0.0052)
125I accumulation was equivalent following IP
injection and vaginal administration in all tissues examined.
Discussion
Here we showed that vaginal administration of PEGLA was
effective as a contraceptive in mice and also that this method of
Figure 2. Intraperitoneal injections of PEGLA reduced bone remodelling in mated and non-mated mice. A & B. Representative Von
Kossa stained tibial sections from mated (A) PEGylation reagent and (B) PEGLA treated mice show reduced trabecular bone (bone stains black).
C–I. Tibial (C) trabecular bone volume (BV/TV), (D) trabecular thickness (TbTh), (E) trabecular number (TbN), (F) osteoid surface (OS/BS), (G) osteoblast
surface (ObS/BS), (H) osteoclast surface (OcS/BS) and (I) osteoclast length (OcL). All values are mean 6 SEM for 4–7 mice per group. *, significant
difference (P,0.05) to PEGylation reagent controls of the same mating status; +, significant difference (P,0.05) to non-mated PEGylation reagent
controls.
doi:10.1371/journal.pone.0019665.g002
Figure 3. Vaginal applications of PEGLA had no effect on bone remodelling in mated mice. A & B. Representative Von Kossa stained
tibial sections from mated (A) PEGMSA and (B) PEGLA treated mice show reduced trabecular bone (bone stains black). C–I. Tibial (C) trabecular bone
volume (BV/TV), (D) trabecular thickness (TbTh), (E) trabecular number (TbN), (F) osteoid surface (OS/BS), (G) osteoblast surface (ObS/BS),
(H) osteoclast surface (OcS/BS) and (I) osteoclast length (OcL). All values are mean 6 SEM for 4–6 mice per group.
doi:10.1371/journal.pone.0019665.g003
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which were observed following IP injection. Further, we showed
that PEGLA had no detectable effect on the CNS based on EAE
induction. This is the first study to demonstrate that a large,
PEGylated protein could be absorbed from the vagina and was
active in the reproductive tract. The physiochemical properties of
drugs are critical for vaginal absorption: the vagina is considered
permeable to low molecular weight, lipophilic and hydrophilic
proteins [41]. PEGLA is a large protein (,60 kDa) but
PEGylation increases water solubility of molecules. This study
suggests that the vagina may be a suitable route of administration
of a LIF antagonist for contraceptive purposes in women,
providing an option for a non-steroidal contraceptive that can
be combined with a microbicidal drug for inhibition of STIs,
including HIV.
Identifying non-uterine targets of PEGLA is critical for its future
contraceptive development. PEGLA had no effect on the CNS
and importantly, although bone was identified as a non-uterine
target of PEGLA following IP injection, no effect on bone was
observed following vaginal application, suggesting that local
administration limited the systemic effects of PEGLA. Only
following IP injection was the specific accumulation of PEGLA in
tissue observed: in the liver, ovary, oviduct, spleen and thyroid in
non-mated females and in the heart of mated females. The long-
term effect of PEGLA on these target tissues should be carefully
evaluated in future studies, however, the elimination of the bone
effect and the lack of specific tissue accumulation of PEGLA
following vaginal administration suggests that local delivery may
minimise any systemic and non-uterine effects of PEGLA.
This study also highlights the potential of vaginal administration
for therapies targeting the female reproductive tract. Vaginally
administered PEGLA localised to the ovary and oviduct more
rapidly and at higher concentrations compared to other organs.
Vaginal administration eliminated non-target, systemic effects of
PEGLA and the dose of PEGLA required to inhibit implantation
following vaginal administration was considerably lower than
following IP injection. This suggests that non-target, systemic
effects of drugs would be significantly diminished by vaginal
administration. Currently, only small molecules such as steroid
hormones are administered vaginally. We suggest that larger
molecules, which have potential to treat pathologies such as
endometrial or ovarian cancer, ectopic pregnancies or endome-
triosis can also be administered vaginally.
IP injection of PEGLA resulted in increased osteoclast number
and size, which is consistent with the reported phenotypes of the
LIF
2/2, CT-1
2/2 and LIFR
2/2 mice [21,22,23]. In contrast,
whilst no change in osteoblast generation was reported in the
LIF
2/2 or LIFR
2/2 phenotypes [21,22], we observed reduced
osteoblast, osteoclast and osteoid surface in PEGLA treated mice
and, only in mated females, increased trabecular bone volume.
The inhibitory effect of a LIFR antagonist on osteoblast
Figure 4. LIF antagonist treatment (Q) did not change EAE severity. EAE grades were recorded for MOG-induced EAE mice treated with PEG
and LIF antagonist.N, PEG; &, LIF antagonist. All values are mean 6 SEM for 8 mice per group.
doi:10.1371/journal.pone.0019665.g004
Figure 5. Circulating
125I following both IP and vaginal
application. A. Circulating
125I in the 120 h following IP injection.
B. Circulating
125I in the 120 h following vaginal application.N,
125I-
PEGLA non-mated; &,
125I-PEGLA mated; e,
125I-PEGBSA non-mated.
*, significant difference (P,0.05) to e.
doi:10.1371/journal.pone.0019665.g005
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and CT-1 stimulate osteoblast differentiation and bone formation
[23,42] and that OSM, acting through LIFR in mice, stimulates
bone formation[43]. It mustbe noted that in this study, PEGylation
reagent control females were pregnant, whereas PEGLA treated
females had failure of implantation and were pseudo-pregnant at
the time of bone collection. Thus, bone remodelling could differ due
to pregnancy status rather than PEGLA treatment. Non-mated
females however showed a similar response to PEGLA treatment,
indicating that PEGLA inhibited bone remodelling regardless of
pregnancy status, although the magnitude of the effect may still be
modulated by pregnancy status.
A possible interaction of mating and pregnancy on bone
metabolism was identified in this study. To date, most studies on
the effects of mating and pregnancy on bone metabolism have
focused on the late stages of pregnancy, when calcium is
transferred to the fetus to allow mineralization of the developing
skeleton [44]. Surprisingly, rapidly decreased trabecular bone
volume and osteoblast surface and increased osteoclast surface
following mating was observed. Whether such rapid bone
Figure 6. Tissue accumulation of
125I-PEGLA and
125I-PEGBSA following IP injection in non-mated (PEGLA: black; PEGBSA: white)
and mated (PEGLA: grey) females. The counts given are normalised to the
125I counts in total blood (counts/ml). A. 2 h post-injection; B. Liver at
24 h post-injection; C. Ovary at 24 h post-injection; D. Oviduct at 24 h post-injection; E. Spleen at 24 h post-injection; F. Thyroid at 24 h post-
injection. *, significant difference between treatment groups (p,0.05).
doi:10.1371/journal.pone.0019665.g006
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is unknown and requires investigation.
While a low level of bone remodelling in growing mice increases
trabecular bone volume [23], low bone remodelling in adult
humans increases fracture risk [45]. This is an important
consideration for long-term management of patients using PEGLA
as a contraceptive. Currently, both the combined oral hormonal
contraceptives (COC) and progestin-only contraceptives (POC)
are associated with changed bone metabolism, including decreased
bone turnover (COC, POC) and bone resorption (POC) [46]. By
contrast, the progestin-releasing intrauterine device Mirena is not
associated with reduced bone mineral density [47], likely because
systemic levels of progestin are minimized by the local site of
administration and the reduced dose required. Thus, local delivery
of PEGLA in women could be expected to reduce effects on bone
metabolism as was found in mice in the present study.
LIF and CNTF are produced in response to an autoimmune
insult within the central nervous system, most likely by reactive
astrocytes to limit immune-mediated demyelination [36]. In mice,
therapeutic recombinant LIF injection ameliorates EAE severity
[36] and systemic injection of neutralizing anti-LIF antibodies
worsens EAE [48]. Here, PEGLA did not worsen EAE severity as
measured by two separate experiments: scoring of motility, and
serum pNF-H levels, which signify axonal injury. Very little
125I-
PEGLA was detected in the brain, further supporting the
suggestion that PEGLA did not enter the CNS, probably due to
the large hydrodynamic volume of PEGylated LA [19]. This
suggests that PEGLA is unlikely to affect LIF action in the CNS
where it plays an important role in oligodendrocyte survival [36].
Conclusion
There is unmet need for contraception worldwide, particularly
in developing countries [49]. Sub-Saharan Africa has the highest
global burden of HIV infection and the majority of new infections
in sub-Saharan Africa are transmitted via heterosexual intercourse
[50]. Vaginally administered ‘dual-role’ contraceptives that also
block HIV infection are highly desirable [49]. PEGLA differs from
current pharmacological contraceptives in that it is non-hormonal
and acts to keep the uterus in a non-receptive state so that
implantation can not occur [19]. This study demonstrated that
vaginal administration of PEGLA inhibited implantation in mice
and abolished the non-target effect on bone and that PEGLA did
not enter the CNS. Future studies are required to demonstrate the
contraceptive efficacy of PEGLA in non-human primates to
progress this research to human clinical trials.
Supporting Information
Figure S1 Inhibition of LIF-induced proliferation of Ba/F3 cells
expressing human LIFR and IL6ST by PEGLA. The maximum
possible value for cell number in this assay was 200.N, PEGLA
(19); &, PEGLA (this study).
(JPG)
Figure S2 Localization of PEGLA and inhibition of implanta-
tion following vaginal application of PEGLA in CAPRISA 400 gel
(1:2 dilution) to mated mice. A–D. PEGLA localization in the
uterine luminal (A&C) and glandular epithelium (B&D), at 3 h
(A&C) and 24 h (B&D) following vaginal application PEGLA.
Arrows indicate positive staining for PEGLA. Insert, negative
control tissue incubated with IgG control at the same concentra-
tion as the primary antibody. Bars 100 mm. E&F. PEGLA
localization in the vaginal epithelium 3 h after a single application
(a) and following repeated applications (106)o f( F) PEGLA.
Arrows indicate positive staining for PEGLA. Insert, negative
control tissue incubated with IgG control at the same concentra-
tion as the primary antibody. Bars 100 mm.
(JPG)
Figure S3 A. Circulating protein bound (TCA-precipitable)
125I
in the 120 h following IP injection. B. Percentage of total
125I
counts in blood that are protein bound (TCA-precipitable) in the
120 h following IP injection. C. Circulating protein bound (TCA-
precipitable)
125I in the 96 h following vaginal application.
D. Percentage of total
125I counts in blood that are protein
bound (TCA-precipitable) in the 96 h following vaginal applica-
tion. N,
125I-PEGLA non-mated; &,
125I-PEGLA mated; e,
125I-
PEGBSA non-mated. *, significant difference (P,0.05) to e.
(JPG)
Figure S4 Tissue accumulation of
125I in the 120 h following IP
injection.N,
125I-PEGLA non-mated; &,
125I-PEGLA mated; e,
125I-
PEGBSA non-mated.
(JPG)
Figure S5 Tissue accumulation of
125I-PEGLA and
125I-
PEGBSA at 2 h (A) and 24 h (B) following IP injection. Thyroid
accumulation not shown due to scale. There was no difference in
thyroid accumulation between the 3 groups. &,
125I-PEGBSA
non-mated; &,
125I-PEGLA non-mated; %
125I-PEGLA mated.
*, significant difference (P,0.05).
(JPG)
Figure S6 Tissue accumulation of 125I in the 24 h following
vaginal application.N,
125I-PEGLA non-mated; &,
125I-PEGLA mated;
e,
125I-PEGBSA non-mated.
(JPG)
Figure S7 Tissue accumulation of
125I-PEGLA and
125I-
PEGBSA at 2 h (A) and 24 h (B) following vaginal application.
Thyroid accumulation not shown due to scale. There was no
difference in thyroid accumulation between the 3 groups. &,
125I-
PEGBSA non-mated; &,
125I-PEGLA non-mated; %
125I-
PEGLA mated. *, significant difference (P,0.05).
(JPG)
Figure S8 Tissue accumulation of
125I-PEGLA normalized to
administered dose in the 24 h following IP injection & and
vaginal application &
125I-PEGLA counts have been normalised
to the total
125I-PEGLA counts administered (%AD, % admin-
istered dose) to allow a comparison between the two delivery
routes. *, significant difference (P,0.05).
(JPG)
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